Terms: = Prostate cancer AND GATA3, HDR, 2625, ENSG00000107485, MGC5445, MGC5199, MGC2346 AND Treatment
598 results:
1. Brachyterapy: The radiation oncologist opinion.
Tagliaferri L; Valentini V
Urologia; 2024 Feb; 91(1):8-10. PubMed ID: 38465607
[TBL] [Abstract] [Full Text] [Related]
2. Development of patient and catheter specific error thresholds for high dose rate prostate brachytherapy.
Koprivec D; Belanger C; Beaulieu L; Chatigny PY; Rosenfeld A; Cutajar D; Petasecca M; Howie A; Bucci J; Poder J
Med Phys; 2024 Mar; 51(3):2144-2154. PubMed ID: 38308854
[TBL] [Abstract] [Full Text] [Related]
3. Establishing a fingerprinting method for fast catheter identification in hdr brachytherapy in vivo dosimetry.
Tho D; Bélanger C; Jørgensen EB; Tanguay J; Rosales HML; Beddar S; Johansen JG; Kertzscher G; Lavallée MC; Beaulieu L
Brachytherapy; 2024; 23(2):165-172. PubMed ID: 38281894
[TBL] [Abstract] [Full Text] [Related]
4. Long-term outcomes of salvage transurethral high-dose-rate brachytherapy combined with external beam radiation therapy for anastomotic recurrence of prostate cancer after radical prostatectomy: A retrospective analysis.
Watanabe K; Kamitani N; Ikeda N; Kawata Y; Tokiya R; Hayashi T; Miyaji Y; Tamada T; Katsui K
Brachytherapy; 2024; 23(2):179-187. PubMed ID: 38245406
[TBL] [Abstract] [Full Text] [Related]
5. Timing of High-Dose-Rate Brachytherapy With External Beam Radiation Therapy in Patients With Intermediate- and High-Risk Localized prostate cancer and Its Effects on Toxicity and Quality of Life: A Randomized Controlled Trial (THEPCA).
Choudhury M; Thomas SS; Cain A; Palvai S; Nageshwaran S; Zhang J; Hayden K; Cain A; Hoskin P; Ahmed I
Int J Radiat Oncol Biol Phys; 2024 May; 119(1):90-99. PubMed ID: 38163520
[TBL] [Abstract] [Full Text] [Related]
6. Safety of high-dose rate (hdr) brachytherapy for patients with prostate cancer and history of prior chemoradiation for rectal cancer: A case series.
Thomas H; Chen JJ; Abdul-Baki H; Sabbagh A; Shaheen H; Chau OW; Malik N; Ayoub A; Hassanzadeh C; Hsu IC; Mohamad O
Brachytherapy; 2024; 23(2):173-178. PubMed ID: 38160102
[TBL] [Abstract] [Full Text] [Related]
7. Clear cell urothelial carcinoma of bladder: Case report of a rare and aggressive variant with review of literature.
Sahetia KM; Dave VN; Pal M; Menon S
Indian J Cancer; 2023 Oct; 60(4):575-577. PubMed ID: 38145907
[TBL] [Abstract] [Full Text] [Related]
8. Characteristics and survival of primary urothelial carcinoma of the prostate: A multi-center retrospective study of 18 cases.
Ji J; Liu T; Yao Y; Liu W; Ning H; Wang T; Zhang G
Neoplasia; 2024 Jan; 47():100961. PubMed ID: 38142529
[TBL] [Abstract] [Full Text] [Related]
9. Prospective study of hdr brachytherapy (BT), external beam radiotherapy (EBRT) and androgen deprivation therapy (ADT): 10-years experience of an MRI-guided approach.
Gomez-Iturriaga A; Zaragoza L; Valverde I; Perez Azorin F; Santos-Zorrozua B; Guerrero JA; Couñago F; Cacicedo J; Marban M; Santana S; Mascarell C; Novo E; Fernandez R; Garcia-Olaverri J; Urresola A; Ezquerro A; Büchser D
Radiother Oncol; 2024 Jan; 190():110024. PubMed ID: 37995851
[TBL] [Abstract] [Full Text] [Related]
10. Aberrant expression of gata3 in metastatic adenocarcinoma of the prostate: an important pitfall.
Lobo J; Tenace NP; Cañete-Portillo S; Carneiro I; Henrique R; Lucianò R; Harik LR; Magi-Galluzzi C
Histopathology; 2024 Feb; 84(3):507-514. PubMed ID: 37965687
[TBL] [Abstract] [Full Text] [Related]
11. Robust stochastic optimization of needle configurations for robotic hdr prostate brachytherapy.
Gerlach S; Siebert FA; Schlaefer A
Med Phys; 2024 Jan; 51(1):464-475. PubMed ID: 37897883
[TBL] [Abstract] [Full Text] [Related]
12. A robust evaluation of 49 high-dose-rate prostate brachytherapy treatment plans including all major uncertainties.
Kennedy AC; Douglass MJJ; Santos AMC
J Appl Clin Med Phys; 2024 Feb; 25(2):e14182. PubMed ID: 37837652
[TBL] [Abstract] [Full Text] [Related]
13. Population-based patient-reported quality of life outcomes following low-dose-rate versus high-dose-rate brachytherapy monotherapy for low-intermediate risk prostate cancer.
Ong WL; Evans M; Papa N; Williams S; Millar J
J Med Imaging Radiat Oncol; 2023 Oct; 67(7):789-795. PubMed ID: 37828817
[TBL] [Abstract] [Full Text] [Related]
14. US-guided EM tracked system for hdr brachytherapy: A first in-men randomized study for whole prostate treatment.
Lavallee MC; Cantin A; Aubin S; Lefebvre M; Marrier AS; Bouchard I; Fiset C; Villeneuve-Gauthier A; Foster W; Martin AG; Carignan D; Beaulieu L; Vigneault E
Brachytherapy; 2024; 23(1):64-72. PubMed ID: 37806788
[TBL] [Abstract] [Full Text] [Related]
15. Analytical hdr prostate brachytherapy planning with automatic catheter and isotope selection.
Frank CH; Ramesh P; Lyu Q; Ruan D; Park SJ; Chang AJ; Venkat PS; Kishan AU; Sheng K
Med Phys; 2023 Oct; 50(10):6525-6534. PubMed ID: 37650773
[TBL] [Abstract] [Full Text] [Related]
16. F-SHARP: a Phase I/II trial of focal salvage high-dose-rate brachytherapy for Radiorecurrent prostate cancer.
Solanki AA; Yoo RK; Adams W; Davicioni E; Mysz ML; Shea S; Gupta GN; Showalter T; Garant A; Hentz C; Farooq A; Baldea K; Small W; Harkenrider MM
BJU Int; 2024 Feb; 133(2):188-196. PubMed ID: 37562825
[TBL] [Abstract] [Full Text] [Related]
17. Clinical characteristics of secondary bladder cancer developing after low-/high-dose-rate brachytherapy to treat localized prostate cancer.
Miyajima K; Suzuki H; Urabe F; Iwatani K; Imai Y; Yasue K; Yanagisawa T; Kimura S; Tashiro K; Tsuzuki S; Koike Y; Miki J; Yuen S; Sasaki T; Aoki M; Sato S; Takahashi H; Miki K; Kimura T
Int J Clin Oncol; 2023 Sep; 28(9):1200-1206. PubMed ID: 37432614
[TBL] [Abstract] [Full Text] [Related]
18. A novel direction modulated brachytherapy technique for urethra sparing in high-dose-rate brachytherapy of prostate cancer.
Meftahi M; Qiu RLJ; Patel P; Song WY; Yang X
Radiother Oncol; 2023 Sep; 186():109801. PubMed ID: 37423478
[TBL] [Abstract] [Full Text] [Related]
19. A two-center experience: The impact of COVID-19 on two brachytherapy programs in Ontario - virtual care, service suspension and radiation therapy workflow.
Chan K; Timotin E; Chung P; Han K; Milosevic M; Schnarr K; Sur R; Bosche J; Harnett N
J Med Imaging Radiat Sci; 2023 Sep; 54(3):436-445. PubMed ID: 37357051
[TBL] [Abstract] [Full Text] [Related]
20. treatment Results of High-dose-rate Brachytherapy and External Beam Radiation With Long-term Androgen Deprivation Therapy for Patients With Metastatic prostate cancer.
Suzuki H; Urabe F; Iwatani K; Miyajima K; Imai YU; Tashiro K; Tsuzuki S; Honda M; Koike Y; Aoki M; Sato S; Takahashi H; Miki K; Kimura T
Anticancer Res; 2023 Jul; 43(7):3135-3143. PubMed ID: 37352008
[TBL] [Abstract] [Full Text] [Related]
[Next]
